Adaptive Biotechnologies (ADPT) – FDA
-
Adaptive Biotechnologies (ADPT) Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
-
Adaptive Biotechnologies (ADPT) Announces Collaboration with Takeda (TAK) to Measure Minimal Residual Disease with clonoSEQ Assay
-
-
-
-
-
-
-
-
-
-
-
Back to ADPT Stock Lookup